The Benign Prostatic Hyperplasia drugs in development market research report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Benign Prostatic Hyperplasia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued products.
GlobalData tracks 29 drugs in development for Benign Prostatic Hyperplasia by 25 companies/universities/institutes. The top development phase for Benign Prostatic Hyperplasia is preclinical with 11 drugs in that stage. The Benign Prostatic Hyperplasia pipeline has 28 drugs in development by companies and one by universities/ institutes. Some of the companies in the Benign Prostatic Hyperplasia pipeline products market are: Yuyu Pharma, Chong Kun Dang Pharmaceutical and Hanmi Pharmaceuticals.
The key targets in the Benign Prostatic Hyperplasia pipeline products market include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35), Alpha 1A Adrenergic Receptor (Alpha 1A Adrenoreceptor or Alpha 1C Adrenergic Receptor or Alpha Adrenergic Receptor 1c or ADRA1A), and Alpha 1D Adrenergic Receptor (Alpha 1A Adrenergic Receptor or Alpha 1D Adrenoreceptor or Alpha Adrenergic Receptor 1a or ADRA1D).
The key mechanisms of action in the Benign Prostatic Hyperplasia pipeline product include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35) Inhibitor with five drugs in Filing rejected/Withdrawn. The Benign Prostatic Hyperplasia pipeline products include eight routes of administration with the top ROA being Oral and five key molecule types in the Benign Prostatic Hyperplasia pipeline products market including Small Molecule, and Synthetic Peptide.
Benign Prostatic Hyperplasia overview
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
For a complete picture of Benign Prostatic Hyperplasia’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
